Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Exclusion Criteria

• •History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
• •Infected with hepatitis B or hepatitis C viruses.
• •Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
• •Have received any of the following treatment regiments specified in the timeframes outlined below:
• •Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving investigational drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated live vaccine.
• •Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.
• •Within 1 week of first dose of study drug: Topical treatments that could affect atopic dermatitis; Herbal medications with unknown properties or known beneficial effects for AD.